INTRODUCTION: Translocation of the anaplastic lymphoma kinase (ALK) gene is involved in the tumorigenesis of a subset of non-small cell lung carcinomas (NSCLCs) and identifies patients sensitive to ALK inhibitors. ALK copy number changes and amplification, which plays an oncogenic role in tumors such as neuroblastoma, are poorly characterized in NSCLC. We aimed to study the prevalence of ALK copy number changes and their correlation to ALK protein expression, epidermal growth factor receptor (EGFR) status, and clinicopathological data in patients with NSCLC. METHODS: ALK status was evaluated by fluorescence in situ hybridization (FISH). Specimens with ALK translocation were studied for echinoderm microtubule-associated protein-like 4 (EML4), KIF5B, and TFG status. ALK expression was assessed by immunohistochemistry. EGFR gene and protein status were evaluated in adenocarcinomas. Survival analysis was performed. RESULTS: One hundred seven NSCLC cases were evaluated. There were two cases of EML4-ALK translocation and one with an atypical translocation of ALK. Both cases of EML4-ALK translocation had ALK protein expression, whereas in the rest, ALK was undetected. Eleven cases (10%) exhibited ALK amplification and 68 (63%) copy number gains. There was an association between ALK amplification and EGFR FISH positivity (p < 0.0001) but not with prognosis. In conclusion, EML4-ALK translocation is a rare event in NSCLC. CONCLUSION: The study reveals a significant frequency of ALK amplification and its association with EGFR FISH positivity in lung adenocarcinomas. Based on these findings, a potential role of ALK amplification in the response to ALK inhibitors alone or combined with EGFR inhibitors in NSCLC merits further studies.
INTRODUCTION: Translocation of the anaplastic lymphoma kinase (ALK) gene is involved in the tumorigenesis of a subset of non-small cell lung carcinomas (NSCLCs) and identifies patients sensitive to ALK inhibitors. ALK copy number changes and amplification, which plays an oncogenic role in tumors such as neuroblastoma, are poorly characterized in NSCLC. We aimed to study the prevalence of ALK copy number changes and their correlation to ALK protein expression, epidermal growth factor receptor (EGFR) status, and clinicopathological data in patients with NSCLC. METHODS:ALK status was evaluated by fluorescence in situ hybridization (FISH). Specimens with ALK translocation were studied for echinoderm microtubule-associated protein-like 4 (EML4), KIF5B, and TFG status. ALK expression was assessed by immunohistochemistry. EGFR gene and protein status were evaluated in adenocarcinomas. Survival analysis was performed. RESULTS: One hundred seven NSCLC cases were evaluated. There were two cases of EML4-ALK translocation and one with an atypical translocation of ALK. Both cases of EML4-ALK translocation had ALK protein expression, whereas in the rest, ALK was undetected. Eleven cases (10%) exhibited ALK amplification and 68 (63%) copy number gains. There was an association between ALK amplification and EGFR FISH positivity (p < 0.0001) but not with prognosis. In conclusion, EML4-ALK translocation is a rare event in NSCLC. CONCLUSION: The study reveals a significant frequency of ALK amplification and its association with EGFR FISH positivity in lung adenocarcinomas. Based on these findings, a potential role of ALK amplification in the response to ALK inhibitors alone or combined with EGFR inhibitors in NSCLC merits further studies.
Authors: Z Ma; J Cools; P Marynen; X Cui; R Siebert; S Gesk; B Schlegelberger; B Peeters; C De Wolf-Peeters; I Wlodarska; S W Morris Journal: Blood Date: 2000-03-15 Impact factor: 22.113
Authors: Maria Paola Martelli; Gabriella Sozzi; Luis Hernandez; Valentina Pettirossi; Alba Navarro; Davide Conte; Patrizia Gasparini; Federica Perrone; Piergiorgio Modena; Ugo Pastorino; Antonino Carbone; Alessandra Fabbri; Angelo Sidoni; Shigeo Nakamura; Marcello Gambacorta; Pedro Luis Fernández; Jose Ramirez; John K C Chan; Walter Franco Grigioni; Elias Campo; Stefano A Pileri; Brunangelo Falini Journal: Am J Pathol Date: 2009-01-15 Impact factor: 4.307
Authors: Scott J Rodig; Mari Mino-Kenudson; Sanja Dacic; Beow Y Yeap; Alice Shaw; Justine A Barletta; Hannah Stubbs; Kenny Law; Neal Lindeman; Eugene Mark; Pasi A Janne; Thomas Lynch; Bruce E Johnson; A John Iafrate; Lucian R Chirieac Journal: Clin Cancer Res Date: 2009-08-11 Impact factor: 12.531
Authors: Rani E George; Takaomi Sanda; Megan Hanna; Stefan Fröhling; William Luther; Jianming Zhang; Yebin Ahn; Wenjun Zhou; Wendy B London; Patrick McGrady; Liquan Xue; Sergey Zozulya; Vlad E Gregor; Thomas R Webb; Nathanael S Gray; D Gary Gilliland; Lisa Diller; Heidi Greulich; Stephan W Morris; Matthew Meyerson; A Thomas Look Journal: Nature Date: 2008-10-16 Impact factor: 49.962
Authors: D Ross Camidge; Margaret Skokan; Porntip Kiatsimkul; Barbara Helfrich; Xian Lu; Anna E Barón; Nathan Schulte; DeLee Maxson; Dara L Aisner; Wilbur A Franklin; Robert C Doebele; Marileila Varella-Garcia Journal: Cancer Date: 2013-09-10 Impact factor: 6.860
Authors: D Ross Camidge; Mariana Theodoro; Delee A Maxson; Margaret Skokan; Tara O'Brien; Xian Lu; Robert C Doebele; Anna E Barón; Marileila Varella-Garcia Journal: Cancer Date: 2012-01-26 Impact factor: 6.860
Authors: E Felip; Á Concha; J de Castro; J Gómez-Román; P Garrido; J Ramírez; D Isla; J Sanz; L Paz-Ares; F López-Ríos Journal: Clin Transl Oncol Date: 2014-10-29 Impact factor: 3.405
Authors: Teresa Morán; Vanesa Quiroga; María de Los Llanos Gil; Laia Vilà; Nuria Pardo; Enric Carcereny; Laia Capdevila; Ana M Muñoz-Mármol; Rafael Rosell Journal: Transl Lung Cancer Res Date: 2013-04